We have located links that may give you full text access.
One-year experience with 68 Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer.
Radiologia Brasileira 2018 May
OBJECTIVE: To show the initial (first-year) experience with 68 Ga-PSMA PET/CT at a clinic in Brazil.
MATERIALS AND METHODS: Over a one-year period, 96 examinations with 68 Ga-PSMA PET/CT (85 related to prostate cancer and 11 related to kidney cancer) were performed in 90 patients.
RESULTS: In the prostate and kidney cancer patients alike, the main clinical indication for 68 Ga-PSMA PET/CT was suspicion of recurrence during follow-up (in 65.8% and 63.0% of the cases, respectively). Among the prostate cancer patients, 38.5% of those with a prostate specific antigen (PSA) < 0.5 ng/mL tested positive for recurrence on 68 Ga-PSMA PET/CT, compared with 71.0% of those with a PSA of 0.5-0.99, 85.7% of those with a PSA of 1.0-1.99, and 92.6% of those with a PSA > 1.99.
CONCLUSION: Although 68 Ga-PSMA PET/CT is a technique that has only recently been applied in clinical settings, despite its high cost, 68 Ga-PSMA PET/CT shows great promise as a tool in the clinical management of patients with kidney and prostate cancer, especially in those with prostate cancer whose PSA levels are elevated even after treatment.
MATERIALS AND METHODS: Over a one-year period, 96 examinations with 68 Ga-PSMA PET/CT (85 related to prostate cancer and 11 related to kidney cancer) were performed in 90 patients.
RESULTS: In the prostate and kidney cancer patients alike, the main clinical indication for 68 Ga-PSMA PET/CT was suspicion of recurrence during follow-up (in 65.8% and 63.0% of the cases, respectively). Among the prostate cancer patients, 38.5% of those with a prostate specific antigen (PSA) < 0.5 ng/mL tested positive for recurrence on 68 Ga-PSMA PET/CT, compared with 71.0% of those with a PSA of 0.5-0.99, 85.7% of those with a PSA of 1.0-1.99, and 92.6% of those with a PSA > 1.99.
CONCLUSION: Although 68 Ga-PSMA PET/CT is a technique that has only recently been applied in clinical settings, despite its high cost, 68 Ga-PSMA PET/CT shows great promise as a tool in the clinical management of patients with kidney and prostate cancer, especially in those with prostate cancer whose PSA levels are elevated even after treatment.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app